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ded in severe Enterobacter (especially), C. freundii,
Serratia and Morganella infections, especially as
there are good therapeutic alternatives with less
risk. The exception would be urinary tract
infections, where the high cephalosporin concen-
trations can overwhelm even derepressed mu-
tants. Finally, the consequences of selecting
derepressed mutants should be re-emphasised.
Recent work by Cosgrove et al. [15] suggested
that selection of cephalosporin resistance in
Enterobacter spp. during therapy was associated
with a doubling of mortality, a median 9-day
increase in hospital stay, and an attributable
cost ⁄ patient of $29 000.
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Use of inhaled ampicillin–sulbactam
against multiresistant Acinetobacter
baumannii in bronchial secretions of
intensive care unit patients
Acinetobacter baumannii is responsible for a wide
range of nosocomial infections, often associated
with ventilated patients in intensive care units
(ICUs) [1]. In a recent Clinical Microbiology and
Infection review, Levin [2] suggested that ampi-
cillin–sulbactam could be used for the treatment
of acinetobacter infections. Most supporting stud-
ies have used intravenous or oral forms of this
antibiotic combination. Here we report the use of
an aerosolised form of ampicillin–sulbactam for
the treatment of ventilated ICU patients.
Twenty intubated, mechanically ventilated
patients (12 male and eight female; aged
38–70 years) were enrolled in the study. Multi-
resistant A. baumannii, sensitive only to ampicillin–
sulbactam, was isolated from the bronchial
secretions of each patient (107)108 CFU ⁄mL).
Patients were randomly assigned to receive
ampicillin–sulbactam in either combined aeroso-
lised and intravenous form (ten patients) or only
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intravenously (ten patients). The dosage of the
aerosolised antibiotic was 3 g in 3 mL of sterile
water administered via a nebuliser every 8 h,
whereas the intravenous ampicillin–sulbactam
was administered in doses of 3 g every 8 h.
Quantitative cultures of bronchial secretions,
together with routine blood chemistry and chest
radiograph results, were obtained on a daily
basis over a 7-day period.
In the patients who received both aerosolised
and intravenous ampicillin–sulbactam, the viable
counts of A. baumannii reduced from 107–108 to
< 102 CFU ⁄mL after 2–3 days of treatment. In
contrast, the counts from the patients who only
received the intravenous antibiotic showed no
significant decrease after 2–3 days, and a decrease
to 105)106 CFU ⁄mL after therapy for 7 days.
A. baumannii is frequently associated in ICU
patients with severe, potentially fatal pneumonia,
as well as multiple antibiotic resistance. This
pathogen is usually acquired exogenously, as it
grows in moist environments and also survives
on the dry surfaces found in ICUs. However, the
usual means of transmission is via the hands of
ICU staff, although several outbreaks have also
been associated with contaminated nebuliser res-
ervoirs or fibreoptic bronchoscopes [3]. Most
infections tend to appear after the second week of
hospitalisation, particularly in patients who are
receiving broad-spectrum antibiotics. Our find-
ings suggest that the addition of aerosolised ampi-
cillin–sulbactam to the standard intravenous
administration of the antibiotic is an effective
means of radically decreasing the level of coloni-
sation of the upper respiratory tract by multire-
sistant A. baumannii in ICU patients, thus
ameliorating a critical risk factor for the develop-
ment of ventilator-associated pneumonia.
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Soft-tissue abscess caused by Salmonella
enterica serovar Enteritidis at the site of
melanoma metastasis
Abscesses caused by Salmonella enterica serovar
Enteritidis are rare in contrast to abscesses caused
by serovars Typhi or Paratyphi [1]. However, a
recent report in Clinical Microbiology and Infection
by Spiritus et al. [2] described an unusual abscess
behind the eye caused by serovar Enteritidis. We
wish to report another unusual location of an
abscess caused by this serovar.
A 54-year-old female, with intrapulmonary and
lymph node metastases and a soft tissue metasta-
sis of malignant melanoma, developed a fever
(39 C) without any clinical signs of sepsis or
gastrointestinal symptoms during her sixth
course of polychemotherapy. Although the stool
cultures were negative, S. enterica serovar Enterit-
idis was isolated from blood culture and was
sensitive to piperacillin–tazobactam and cefurox-
ime. At the site of the soft tissue metastasis on the
left flank, there was a hyperthermic and painful
infiltrate without any fluctuation. Ultrasonogra-
phy showed a subcutaneous solid mass with a
surrounding inflammatory infiltrate. The patient
was treated with intravenous piperacillin–tazo-
bactam 4.5 g every 8 h for 6 days, after which the
blood culture and temperature were normal. The
infiltrate on the left flank improved noticeably.
Four days later, the patient developed a fever
(40 C) and clinical signs of an abscess at the
location of the soft tissue metastasis. Microbiolo-
gical examination of the abscess revealed
S. enterica serovar Enteritidis. The abscess healed
completely following treatment with intravenous
piperacillin–tazobactam for a further 7 days and
oral cefuroxime for 6 weeks.
The patient may have been infected 4 weeks
earlier in hospital when she ate a dessert consist-
ing of a pear with blancmange. Several other
patients suffered with diarrhoea at that time, and
serovar Enteritidis was isolated from their stool
cultures. Further investigations revealed that the
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